Sun Mar 30 22:50:00 UTC 2025: ## Eli Lilly Drug Shows Promise in Lowering Heart Attack Risk Factor

**New York, NY** – A new experimental drug from Eli Lilly, lepodisiran, has shown remarkable success in significantly lowering levels of Lp(a), a blood particle linked to increased risk of heart attacks and strokes. Results presented at the American College of Cardiology’s annual meeting and published in the *New England Journal of Medicine* revealed a 94% reduction in Lp(a) levels after a single injection, with effects lasting six months and minimal side effects.

Affecting an estimated 64 million Americans, elevated Lp(a) has been a significant concern due to the lack of effective treatments. Previous attempts to manage Lp(a) through diet and exercise have proven ineffective. This breakthrough offers new hope for millions.

While the results are highly encouraging, researchers emphasize that large-scale clinical trials are still underway to definitively prove that lowering Lp(a) levels translates to a reduced risk of cardiovascular events. However, Dr. David Maron of Stanford University described the findings as “thrilling,” highlighting the drug’s profound and sustained impact on Lp(a) levels.

At least four other pharmaceutical companies are also developing similar drugs targeting Lp(a) production, indicating a significant push towards addressing this previously intractable risk factor for heart disease. The findings represent a major step forward in the fight against cardiovascular disease, but further research is crucial to confirm the life-saving potential of this new approach.

Read More